Bayer's Dual Front: Legal Relief Meets US Pharma Revamp

Bayer sees legal clarity on glyphosate and a new US pharma strategy to offset patent cliffs, backed by growth drugs like Kerendia and a stable 2026 forecast.

Investors in Bayer AG are navigating a complex landscape where a potential easing of long-standing legal pressures coincides with a strategic overhaul of its crucial US pharmaceuticals business. The convergence of these developments is reshaping the risk profile for the embattled conglomerate.

A significant shift in sentiment is emerging from analysts. DZ Bank upgraded its rating on Bayer shares to "Hold" this week, citing improved predictability surrounding the US glyphosate litigation. While operational challenges persist, the bank sees earnings prospects stabilizing. A pivotal $7.25 billion settlement proposal has received preliminary court approval, and a landmark decision from the US Supreme Court is anticipated on April 27, 2026. This legal clarity is being welcomed by the market; shares closed at EUR 40.12 on Friday, marking a solid year-to-date gain of 5.51%.

Parallel to these judicial maneuvers, Bayer is executing a strategic pivot in its largest pharmaceutical market. Effective May 1, 2026, Nelson Ambrogio will take the helm of Bayer U.S. Pharmaceuticals. The move is a direct response to the looming patent expirations for blockbuster drugs Xarelto and Eylea. The company is banking on its next-generation portfolio to fill the impending revenue gap.

Leading this charge is the heart failure drug Kerendia, which saw sales surge nearly 93% to EUR 264 million in the fourth quarter of 2025. Its annual revenue reached EUR 829 million, with Bayer targeting peak annual sales of EUR 3 billion. The drug recently received an expanded EU approval for a new heart failure indication, providing additional momentum. This product is part of a broader growth engine that includes Nubeqa for prostate cancer, Lynkuet for non-hormonal menopause management, and Asundexian for secondary stroke prevention.

The company's ambitions extend beyond its current pipeline. By leveraging proprietary AI tools and external partnerships, Bayer aims to boost research productivity by 40% by 2030, a critical goal for ensuring a steady stream of new treatments. Financially, management has confirmed its 2026 EBITDA forecast of EUR 9.6 to 10.1 billion, noting that current US-EU trade frameworks, which cap tariffs on European pharma products at 15%, are already factored into its plans.

Corporate governance is also in flux. At the virtual Annual General Meeting on April 24, 2026, shareholders will vote on appointing Alfred Stern, CEO of OMV, and former Cargill executive Marcel Smits to the Supervisory Board. They would replace Paul Achleitner and Colleen A. Goggins, bolstering the board's expertise in energy and agriculture. Following the meeting, a dividend of EUR 0.11 per share for the past fiscal year will be paid on April 29.

The coming weeks will test both strands of Bayer's strategy. On May 12, 2026, the company will release its first-quarter financial results. This report will include the management's first official commentary on the ongoing glyphosate proceedings—a moment investors have long awaited. If the operational momentum from drugs like Kerendia holds, that commentary could become the primary catalyst for the stock's next move.